Adcendo is a biotech company developing antibody-drug conjugates (ADCs) for cancer treatment. ADCs are an emerging drug modality directing anticancer therapeutics to malignant cells overexpressing particular surface target molecules.

Adcendo

Adcendo seeks to develop antibody-drug conjugates to create new medicines for cancer patients with a significant unmet need. 

The company was founded in 2017 in Copenhagen, as a spin-out from The Finsen Laboratory of Rigshospitalet and the University of Copenhagen. 

Novo Nordisk Foundation

Ysios Capital

Dawn Biopharma

RA Capital Management

Gilde Healthcare

HealthCap

Novo Holdings

Pontifax

Adcendo Stands with the Sarcoma Community: Advancing Innovation for a Brighter Future

This July, as we observe Sarcoma Awareness Month, Adcendo reaffirms our commitment to the global fight against sarcoma. Sarcoma Awareness Month is a powerful reminder of the strength and resilience of those affected by this rare group of cancers, and it is a call to action for all to raise awareness and drive innovation.

At Adcendo, we are pioneering the development of Antibody-Drug Conjugates (ADCs) specifically designed to target rare cancers such as sarcomas. Our mission is to transform the treatment landscape for sarcoma patients by harnessing the power of ADC technology to deliver targeted, effective therapies. 

Our lead program focuses on uPARAP (urokinase plasminogen activator receptor-associated protein), a novel and promising target for cancer treatment, underscoring our dedication to addressing the unmet needs in sarcoma care.

We believe that through cutting-edge research and collaboration, we can make a significant impact. This Sarcoma Awareness Month, we invite patients, families, caregivers, healthcare professionals, researchers, policymakers, and the broader community to join us in our mission. 

Together, we can honour those who have battled sarcoma, support those currently fighting, and work towards a future where early detection, effective treatment, and ultimately, a cure for sarcoma, are within reach.

Join Adcendo in standing with the sarcoma community and reinforcing our collective commitment to innovative cancer treatment solutions.

#SarcomaAwarenessMonth #Adcendo #InnovationInAction #CancerResearch #ADCTechnology #HopeForACure

Join Adcendo as our new Assoc. Director / Director, Business Development and Alliance Management. 🚀

At Adcendo, we are dedicated to developing highly differentiated antibody-drug conjugates (ADCs) for the treatment of underserved cancers. We pride ourselves on being at the forefront of cutting-edge technologies and solutions, and our commitment to excellence sets us apart. 

We offer an international work environment that fosters innovation and rewards excellence. This is a fantastic opportunity to contribute to the future of cancer treatment as part of a forward-thinking company!

Find more details about the job and how to apply: https://lnkd.in/dCsPmvNw
 
#BusinessDevelopment #AllianceManagement #Adcendo #CareerOpportunity #JobOpening

Please join us in welcoming our newest team member, Sandra Thomas Frederiksen, who has joined us as Executive Assistant. 

Her extensive experience supporting leaders in the Biotech industry will undoubtedly contribute to our success!

Welcome to Adcendo, Sandra! We look forward to the exciting journey ahead as we make strides towards better treatment of cancer. 🚀
 
Follow our Company LinkedIn page for news and information about upcoming open positions.
 
#Adcendo #NewHire #CancerResearch #ADCs #ExecutiveAssistant #WeAreGrowing

Great to see our CEO, Michael Pehl, highlighted by Clarivate following the publication of its 'Companies to Watch: Antibody Drug Conjugates' report!

https://lnkd.in/dbTeNsct

Learn more about Adcendo and our development of first-in-class #ADCs for the treatment of #cancer with a high unmet medical need in the report here: https://lnkd.in/eWhSzAWz

#biotech #oncology #lifesciences

📣 Adcendo has been featured in Clarivate for Life Sciences & Healthcare's "Companies to Watch: Antibody Drug Conjugates" report! 📰 

The report highlights this exciting field of therapeutics and shines a spotlight on companies making an impact in the #lifesciences and #healthcare space. Adcendo is highlighted as one of seven companies that are advancing antibody-drug conjugates (#ADCs) to deliver highly targeted cancer treatments with an improved therapeutic window.

Find out more about what makes us stand out, our R&D activities to date, and much more in the report here: https://lnkd.in/eWhSzAWz

#biotech #oncology #lifesciences

Meet our Head of Business Development James at LSX World in London! 👨‍💼 

https://lnkd.in/ddbtpquX

COM:ADCENDO

Adcendo

Financials Not Available